HLX301

TIGIT×PD-L1 bispecific · Shanghai Henlius Biotech

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for HLX301, covering 2023-08-08 to 2023-08-08. Get the full timeline:

Most recent: Clinical Trial Update: A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma [Phase 1, Phase 2]

See pricing